The 21 references in paper E. Kropacheva S., E. Panchenko P., Е. Кропачева С., Е. Панченко П. (2017) “ВЫБОР ОПТИМАЛЬНОЙ ДЛИТЕЛЬНОЙ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ С РЕЦИДИВИРУЮЩИМИ МАЛЫМИ КРОВОТЕЧЕНИЯМИ. КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ // SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP” / spz:neicon:aterotromboz:y:2017:i:1:p:105-113

1
Onundarson PT, Thorgeirsson G, Jonmundsson E et al. Chronic atrial fibrillation — Epidimiologic features and 14 year follow-up: A case control study. Eur Heart J,1987, 3: 521-27.
(check this in PDF content)
2
Flegel KM, Shipley MJ, Rose G “Risk of stroke in nonrheumatic atrial fibrillation. Lancet,1987, 1: 526-529.
(check this in PDF content)
3
Tanaka H, Hayashi M, Date C et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: Preliminary report on risk factors for cerebral infarction. Stroke,1985, 16: 773-780.
(check this in PDF content)
4
Mondillo S, Sabatini L,Agricola E et al. Correlation between left atrial size, prothrombotic state and marcers of endotelian dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol,2000 Sep 15, 75(2-3): 227-32.
(check this in PDF content)
5
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. New England Journal of Medicine, 2002, 347: 1825-33.
(check this in PDF content)
6
Hohnloser SH, Kuck K-H, Lilienthal J for the PIAF Investigators Rhythm or rate control in atrial fibrillation — Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. The Lancet, 2000, 356: 1789-1794.
(check this in PDF content)
7
Stollberger C, Chnupa P, Kronik G. Embolism in leftatrial thrombi (ELAT Study): are spontaneous echo contrast, thrombi in the left atrium appendage and size of the left atrial appendage predictors of possible embolisms? Wien Med Wochenschr,1997, 147(2): 46-51.
(check this in PDF content)
8
Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by Transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography. Ann Inter Med,1997 Feb 1, 126(3): 200-9.
(check this in PDF content)
9
Fatkin D, Kelly RP, Feneley MP. Relation between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. JACC,1994, 23: 961-9.
(check this in PDF content)
10
Feinberg WM, Seeger JF. Epidemiological features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Intern Med, 150: 2340-44.
(check this in PDF content)
11
Chatzikonstantinou A, Wolf ME, Schaefer A, Hennerici MG. Risk prediction of subsequent early stroke in patients with transient ischemic attacks. Cerebrovasc Dis, 2013, 36(2): 106-9. doi: 10.1159/000352060.
(check this in PDF content)
12
Christensen H, Fogh Christensen A, Boysen G. Abnormalities on ECG and telemetry predict stroke outcome at 3 months. J Neurol Sci, 2005 Jul 15, 234(1-2): 99-103.
(check this in PDF content)
13
ACC/AHA/ESC guidelines for the managemen to patients with atrial fibrillation, 2001.
(check this in PDF content)
14
Olesen JB, Lip GY, Hansen PR et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two establishedbleeding prediction schemes in a nationwide cohort. J Thromb Haemost, 2011, 9(8): 1460-7.
(check this in PDF content)
15
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J, 2012, 33(12): 1500-10.
(check this in PDF content)
16
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol, 2011, 57(2):
(check this in PDF content)
17
80. 17. Mhairi Copland, Walker ID, Campbell R. Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. Arch Inter Med,2001, 161, 61(17): 2125-8.
(check this in PDF content)
18
Connolly SJ, Ezekowitz MD, Salim Yusuf et al and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med,2009, 361: 1139-1151. DOI: 10.1056/NEJMoa090556123.
(check this in PDF content)
19
Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). AHJ, 2012, 163(1): 13-19.
(check this in PDF content)
20
Гуськова Е.В., Панченко Е.П., Комаров А.Л. и соавт. Показатели гемостаза и прогноз тромботических и геморрагических осложнений у больных ИБС после плановых чрескожных коронарных вмешательств. Кардиологический вестник, 2015, 10(3): 54-63.
(check this in PDF content)
21
Кропачева Е.С., Землянская О.А., Панченко Е.П. и соавт. Безопасность длительной терапии варфарином: частота кровотечений и клинические предикторы их развития (результаты проспективного 15-летнего наблю-
(check this in PDF content)